Schedule 13D ownership disclosure
Zentalis Pharmaceuticals, Inc.
Security class unavailable · CUSIP: 98943L107
Event date: 2022-05-18
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 9,199,973
- Percent of class
- 16.4500%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-22-003160
- Form type
- SC 13D
- Filer
- Matrix Capital Management Company, LP
- CIK
- CIK 1410830
- Filed
- Jun 03, 2022
- Reporting period
- May 18, 2022
- Description
- Schedule 13D beneficial ownership